Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

• Characterize the overall safety and tolerability of ridaforolimus in combination with bevacizumab [ Time Frame: Duration of the study ] [ Designated as safety issue: Yes ]
• Description of the anti-tumor activity of ridaforolimus in combination with bevacizumab [ Time Frame: Duration of the study ] [ Designated as safety issue: No ]

• Characterize the overall safety and tolerability of deforolimus in combination with bevacizumab [ Time Frame: Duration of the study ] [ Designated as safety issue: Yes ]
• Description of the anti-tumor activity of deforolimus in combination with bevacizumab [ Time Frame: Duration of the study ] [ Designated as safety issue: No ]

The purpose of this study is to assess the safety, tolerability, and recommended phase 2 dose of oral ridaforolimus administered in combination with intravenous bevacizumab in patients with advanced cancers.

• Drug: ridaforolimus
  oral tablets, daily for 5 days/week
  Other Names:

  • deforolimus
  • AP23573
  • MK-8669
  • ridaforolimus was also known as deforolimus until May 2009
• Drug: bevacizumab
  IV infusion
  Other Name: avastin

• Experimental: 1
  30mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
  Interventions:

  • Drug: ridaforolimus
  • Drug: bevacizumab
• Experimental: 2
  40mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
  Interventions:

  • Drug: ridaforolimus
  • Drug: bevacizumab
• Experimental: 3
  40mg QDx5/wk ridaforolimus plus 15mg/kg Q3wks bevacizumab for 3 weeks
  Interventions:

  • Drug: ridaforolimus
  • Drug: bevacizumab

Inclusion Criteria:

• 18 years of age or older
• Advanced or metastatic solid tumor malignancy
• ECOG performance status of less than or equal to 1
• Life expectancy of greater than 3 months
• At least 4 weeks must have elapsed between prior investigational therapy, chemotherapy, or radiotherapy, and the first dose of deforolimus
• Adequate hematological, hepatic and renal function
• Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal to 400 mg/dL
• Signed informed consent
• Women of childbearing potential must have a negative serum pregnancy test within 7 days of starting therapy and must use an approved contraceptive method from time of screening until 30 days after the last dose of study drug

Exclusion Criteria:

• Tumor location in close proximity to a major blood vessel
• History of brain metastases, spinal cord compression, or carcinomatous meningitis. Primary brain tumors (for example, glioblastoma) are allowed.
• New brain metastases, spinal cord compression, or leptomeningeal metastases on screening CT scan or MRI
• Hemoptysis or hematemesis within 28 days prior to entering the trial
• Clinical significant unexplained bleeding within 28 days prior to entering the trial
• Uncontrolled hypertension
• Proteinuria at screening
• Clinically significant cardiovascular disease
• Newly diagnosed or poorly controlled type 1 or 2 diabetes
• Active infection requiring prescribed intervention
• Other concurrent illness that, in the Investigator's judgement, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug
• Major surgery within 28 days before trial entry, or any incompletely healed surgical incision; minor surgery or procedures within 7 days
• Pregnant or breastfeeding
• Known allergy to macrolide antibiotics
• Known hypersensitivity to any component of bevacizumab
• Concurrent treatment with medications that strongly induce or inhibit cytochrome P450 (CYP3A)
• Known history of HIV sero-positivity
• Any condition in the Investigator's judgement that renders the patient unable to fully understand and provide informed consent and/or comply with the protocol